Icosapent Ethyl

CHEMBL2095209 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
330.5 g/mol
LogP
6.3
Phase
4

This purified omega-3 fatty acid ethyl ester, derived from fish oil, is used to reduce cardiovascular risk in adults with elevated triglycerides alongside statin therapy. Unlike other fish oil supplements, it contains only EPA (eicosapentaenoic acid) without DHA, which is thought to contribute to its unique cardiovascular benefits. It has been shown to significantly reduce major adverse cardiovascular events.

分子量

330.5000 g/mol

LogP

6.30

TPSA

26.30 Ų

リピンスキーの五則

適合

治療領域

作用機序

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC

InChI

InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-

Molecular Formula

C22H34O2

HBD / HBA

- / 2

回転可能結合数

15

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This purified omega-3 fatty acid ethyl ester, derived from fish oil, is used to reduce cardiovascular risk in adults with elevated triglycerides alongside statin therapy. Unlike other fish oil supplements, it contains only EPA (eicosapentaenoic acid) without DHA, which is thought to contribute to its unique cardiovascular benefits. It has been shown to significantly reduce major adverse cardiovascular events.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Icosapent Ethyl is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2095209. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9831415. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.